Atomic AI

0 reviews

Atomic AI is a biotechnology company at the forefront of integrating artificial intelligence with structural biology to revolutionize RNA drug discovery. By combining advanced machine learning models with proprietary wet-lab assays, Atomic AI's Platform for AI-driven RNA Structure Exploration (PARSE) enables the development of highly potent and selective RNA-targeted small molecules and RNA-based medicines. This innovative approach addresses diseases traditionally considered undruggable at the protein level, particularly in oncology and neurodegenerative disorders. Key Features and Functionality: - PARSE Platform: A proprietary R&D platform that merges deep learning foundation models with in-house wet-lab assays to discover and develop RNA-targeted therapeutics. - ATOM-1™ Model: A pioneering large language model utilizing chemical mapping data to predict RNA structural and functional properties, enhancing the design of RNA-based modalities such as small molecules, mRNA vaccines, siRNAs, and circular RNA. - Interdisciplinary Expertise: A team of specialists in machine learning, RNA biology, and drug discovery, committed to bold innovation and collaborative problem-solving. Primary Value and Problem Solved: Atomic AI's platform overcomes a significant barrier in drug discovery by enabling the targeting of RNA structures, which were previously considered undruggable at the protein level. This capability opens new avenues for treating complex diseases, particularly in oncology and neurodegenerative conditions, by developing highly selective RNA-targeted small molecule splicing modulators. By harnessing the synergy between AI and structural biology, Atomic AI accelerates the development of innovative therapeutics, offering hope for patients with limited treatment options.